Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors

Shinsuke Kato, Kenji Ishihara, Takao Shinozawa, Hiroyuki Yamaguchi, Yoshiya Asano, Masaya Saito, Masako Kato, Tadashi Terada, Akira Awaya, Asao Hirano, Dennis W. Dickson, Shu Hui Yen, Eisaku Ohama

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We produced a rat IgG2a monoclonal antibody against the carboxyl terminal region of human midkine (MK), a novel growth factor. This monoclonal antibody was used in immunohistochemical studies to compare the expression of MK, proliferating cell nuclear antigen (PCNA) and p53 protein in 133 primary brain tumors and 21 carcinoma metastases to the central nervous system. Approximately half of the glioblastomas multiforme (GBMs) (19/32), medulloblastomas (8/14), primitive neuroectodermal tumors (PNETs) (5/11), breast carcinoma metastases (Br-Mts) (6/10) and lung carcinoma metastases (L- Mts) (5/11) as well as some astrocytomas (2/14) had tumor cells that expressed MK; however, oligodendrogliomas, ependymomas, schwannomas, meningiomas, and pituitary adenomas did not express MK. The values of the PCNA-labeling index were statistically higher in GBMs, medulloblastomas, PNETs, Br-Mts, and L-Mrs that expressed MK than in those that did not (Wilcoxon rank-sum test, p < 0.05). There was no correlation between MK and p53 protein in all tumor types. Normal and non-neoplastic brain tissues were negative for MK, PCNA, and p53 protein. We conclude that primary and metastatic tumors of the brain express MK and that the MK expression in brain tumors may depend, in part, on the proliferating potential.

Original languageEnglish (US)
Pages (from-to)430-441
Number of pages12
JournalJournal of Neuropathology and Experimental Neurology
Volume58
Issue number5
StatePublished - 1999

Fingerprint

Brain Neoplasms
Monoclonal Antibodies
Proliferating Cell Nuclear Antigen
Neoplasm Metastasis
Primitive Neuroectodermal Tumors
Medulloblastoma
Glioblastoma
Nonparametric Statistics
Breast Neoplasms
Carcinoma
Oligodendroglioma
midkine
Ependymoma
Proteins
Neurilemmoma
Astrocytoma
Pituitary Neoplasms
Meningioma
Neoplasms
Intercellular Signaling Peptides and Proteins

Keywords

  • Brain tumor
  • Glioblastoma multiforme
  • Immunohistochemistry
  • Midkine
  • Monoclonal antibody
  • p53 protein
  • Proliferating cell nuclear antigen

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Kato, S., Ishihara, K., Shinozawa, T., Yamaguchi, H., Asano, Y., Saito, M., ... Ohama, E. (1999). Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors. Journal of Neuropathology and Experimental Neurology, 58(5), 430-441.

Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors. / Kato, Shinsuke; Ishihara, Kenji; Shinozawa, Takao; Yamaguchi, Hiroyuki; Asano, Yoshiya; Saito, Masaya; Kato, Masako; Terada, Tadashi; Awaya, Akira; Hirano, Asao; Dickson, Dennis W.; Yen, Shu Hui; Ohama, Eisaku.

In: Journal of Neuropathology and Experimental Neurology, Vol. 58, No. 5, 1999, p. 430-441.

Research output: Contribution to journalArticle

Kato, S, Ishihara, K, Shinozawa, T, Yamaguchi, H, Asano, Y, Saito, M, Kato, M, Terada, T, Awaya, A, Hirano, A, Dickson, DW, Yen, SH & Ohama, E 1999, 'Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors', Journal of Neuropathology and Experimental Neurology, vol. 58, no. 5, pp. 430-441.
Kato, Shinsuke ; Ishihara, Kenji ; Shinozawa, Takao ; Yamaguchi, Hiroyuki ; Asano, Yoshiya ; Saito, Masaya ; Kato, Masako ; Terada, Tadashi ; Awaya, Akira ; Hirano, Asao ; Dickson, Dennis W. ; Yen, Shu Hui ; Ohama, Eisaku. / Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors. In: Journal of Neuropathology and Experimental Neurology. 1999 ; Vol. 58, No. 5. pp. 430-441.
@article{ae87e1aaef0d4a2faf6d3d8cd0f6f880,
title = "Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors",
abstract = "We produced a rat IgG2a monoclonal antibody against the carboxyl terminal region of human midkine (MK), a novel growth factor. This monoclonal antibody was used in immunohistochemical studies to compare the expression of MK, proliferating cell nuclear antigen (PCNA) and p53 protein in 133 primary brain tumors and 21 carcinoma metastases to the central nervous system. Approximately half of the glioblastomas multiforme (GBMs) (19/32), medulloblastomas (8/14), primitive neuroectodermal tumors (PNETs) (5/11), breast carcinoma metastases (Br-Mts) (6/10) and lung carcinoma metastases (L- Mts) (5/11) as well as some astrocytomas (2/14) had tumor cells that expressed MK; however, oligodendrogliomas, ependymomas, schwannomas, meningiomas, and pituitary adenomas did not express MK. The values of the PCNA-labeling index were statistically higher in GBMs, medulloblastomas, PNETs, Br-Mts, and L-Mrs that expressed MK than in those that did not (Wilcoxon rank-sum test, p < 0.05). There was no correlation between MK and p53 protein in all tumor types. Normal and non-neoplastic brain tissues were negative for MK, PCNA, and p53 protein. We conclude that primary and metastatic tumors of the brain express MK and that the MK expression in brain tumors may depend, in part, on the proliferating potential.",
keywords = "Brain tumor, Glioblastoma multiforme, Immunohistochemistry, Midkine, Monoclonal antibody, p53 protein, Proliferating cell nuclear antigen",
author = "Shinsuke Kato and Kenji Ishihara and Takao Shinozawa and Hiroyuki Yamaguchi and Yoshiya Asano and Masaya Saito and Masako Kato and Tadashi Terada and Akira Awaya and Asao Hirano and Dickson, {Dennis W.} and Yen, {Shu Hui} and Eisaku Ohama",
year = "1999",
language = "English (US)",
volume = "58",
pages = "430--441",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors

AU - Kato, Shinsuke

AU - Ishihara, Kenji

AU - Shinozawa, Takao

AU - Yamaguchi, Hiroyuki

AU - Asano, Yoshiya

AU - Saito, Masaya

AU - Kato, Masako

AU - Terada, Tadashi

AU - Awaya, Akira

AU - Hirano, Asao

AU - Dickson, Dennis W.

AU - Yen, Shu Hui

AU - Ohama, Eisaku

PY - 1999

Y1 - 1999

N2 - We produced a rat IgG2a monoclonal antibody against the carboxyl terminal region of human midkine (MK), a novel growth factor. This monoclonal antibody was used in immunohistochemical studies to compare the expression of MK, proliferating cell nuclear antigen (PCNA) and p53 protein in 133 primary brain tumors and 21 carcinoma metastases to the central nervous system. Approximately half of the glioblastomas multiforme (GBMs) (19/32), medulloblastomas (8/14), primitive neuroectodermal tumors (PNETs) (5/11), breast carcinoma metastases (Br-Mts) (6/10) and lung carcinoma metastases (L- Mts) (5/11) as well as some astrocytomas (2/14) had tumor cells that expressed MK; however, oligodendrogliomas, ependymomas, schwannomas, meningiomas, and pituitary adenomas did not express MK. The values of the PCNA-labeling index were statistically higher in GBMs, medulloblastomas, PNETs, Br-Mts, and L-Mrs that expressed MK than in those that did not (Wilcoxon rank-sum test, p < 0.05). There was no correlation between MK and p53 protein in all tumor types. Normal and non-neoplastic brain tissues were negative for MK, PCNA, and p53 protein. We conclude that primary and metastatic tumors of the brain express MK and that the MK expression in brain tumors may depend, in part, on the proliferating potential.

AB - We produced a rat IgG2a monoclonal antibody against the carboxyl terminal region of human midkine (MK), a novel growth factor. This monoclonal antibody was used in immunohistochemical studies to compare the expression of MK, proliferating cell nuclear antigen (PCNA) and p53 protein in 133 primary brain tumors and 21 carcinoma metastases to the central nervous system. Approximately half of the glioblastomas multiforme (GBMs) (19/32), medulloblastomas (8/14), primitive neuroectodermal tumors (PNETs) (5/11), breast carcinoma metastases (Br-Mts) (6/10) and lung carcinoma metastases (L- Mts) (5/11) as well as some astrocytomas (2/14) had tumor cells that expressed MK; however, oligodendrogliomas, ependymomas, schwannomas, meningiomas, and pituitary adenomas did not express MK. The values of the PCNA-labeling index were statistically higher in GBMs, medulloblastomas, PNETs, Br-Mts, and L-Mrs that expressed MK than in those that did not (Wilcoxon rank-sum test, p < 0.05). There was no correlation between MK and p53 protein in all tumor types. Normal and non-neoplastic brain tissues were negative for MK, PCNA, and p53 protein. We conclude that primary and metastatic tumors of the brain express MK and that the MK expression in brain tumors may depend, in part, on the proliferating potential.

KW - Brain tumor

KW - Glioblastoma multiforme

KW - Immunohistochemistry

KW - Midkine

KW - Monoclonal antibody

KW - p53 protein

KW - Proliferating cell nuclear antigen

UR - http://www.scopus.com/inward/record.url?scp=0032920817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032920817&partnerID=8YFLogxK

M3 - Article

C2 - 10331431

AN - SCOPUS:0032920817

VL - 58

SP - 430

EP - 441

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 5

ER -